Clinical Trials Browser

Interventional × luspatercept × Myeloid × Clear all

NCT05564390 2026-03-18

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05732961 2025-12-10

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

Phase 2 Recruiting

Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT04064060 2025-11-12

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Phase 3 Recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT04717414 2025-07-10

INDEPENDENCE

Phase 3 Active not recruiting

Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

NCT06927232 2025-04-15

AZA+Lus VS AZA Monotherapy in HR-MDS

Phase 3 Not yet recruiting

Higher-risk Myelodysplastic Syndrome

NCT05005182 2024-09-19

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Phase 2 Terminated

3 enrolled 12 charts

Myeloproliferative Disorders, Thrombocytosis

NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Phase 2 Completed

95 enrolled 32 charts

Classical hematologyMyeloid

Anemia, Primary Myelofibrosis

NCT02631070 2021-12-17

MEDALIST

Phase 3 Completed

229 enrolled 36 charts 2 FDA

Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes